​​SENVELGO® wins Best New Product for Companion Animals award​ 

S&P Global has recognized SENVELGO^®, Boehringer Ingelheim’s groundbreaking feline diabetes innovation, with the Animal Health Award 2023 in the category “Best New Product for Companion Animals”. A group of independent judges chose SENVELGO^® because of its indication in a new product category (SGLT2 inhibitors), its milestone approvals in the US, Canada and Europe this year, and because it was designed specifically for cats.

“The overwhelming excitement for SENVELGO^® from our customer veterinarians was a first indication of the value this product brings and the impact on the lives of cats and their owners. We are honored to now receive this award for the Best New Product for Companion Animals,” shares Jean-Luc Michel, Head of Global Strategic Marketing Animal Health at Boehringer Ingelheim.

The Best New Product for Companion Animals award is aimed at products for dogs, cats, or horses that were commercialized in 2023 or completed their first full year of sales in 2023. The winning criteria include innovation, the product's ability to meet unmet needs, and its success in the market. 

SENVELGO^® revolutionizes care for diabetic cats 

SENVELGO^® is the first once daily oral liquid treatment which reliably reduces blood glucose levels in cats with diabetes mellitus. It makes treating a diabetic cat simple and convenient, allowing diabetic cats and their owners to have normal lives despite the disease.

Eric Haaksma, Head of Global Innovation Animal Health at Boehringer Ingelheim, comments: “People go above and beyond to protect or treat their pets from illnesses and improve their quality of life. At Boehringer Ingelheim, our ambition is to transform the lives of animals and their owners through new approaches and innovative treatments. SENVELGO^® exemplifies this ambition, and receiving this award is a wonderful recognition of the dedicated efforts of our teams.” 

SENVELGO^® is already being sold in veterinary clinics in the US, Great Britain, and Switzerland, and recently received regulatory approval in the European Union and Canada.

Boehringer Ingelheim Animal Health 

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both. For more information visit: https://www.boehringer-ingelheim.com/animal-health  

Boehringer Ingelheim 

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com 

Intended Audiences Notice 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.